Oncotelic Therapeutics Inc. (OTLC)

Overview

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutic solutions for orphan oncology indications. With its operations based in Agoura Hills, California, the company is deeply involved in advancing its proprietary drug candidates through various stages of clinical trials. Oncotelic’s approach to combating cancer and viral infections involves antisense technologies, angiogenesis inhibitors, and advanced drug delivery systems. By targeting specific molecular pathways, Oncotelic aims to provide novel treatments for deadly diseases such as pancreatic cancer, glioblastoma, acute myeloid leukemia, myelodysplastic syndromes, and metastatic melanoma, as well as for neurological conditions and viral infections.

Products and Services

• OT-101

  Oncotelic’s flagship candidate, OT-101, is an antisense oligonucleotide designed to target transforming growth factor-beta 2 (TGF-ß2). It is currently being evaluated in phase 3 clinical trials for its efficacy against pancreatic cancer and glioblastoma. Beyond its applications in oncology, OT-101 is also under development for its potential in treating various viral infections, including severe acute respiratory syndrome and coronavirus, showcasing the versatility and broad therapeutic potential of this molecule.

• OXi4503

  This is a dual-action compound aimed at treating acute myeloid leukemia and myelodysplastic syndromes. OXi4503's mechanism involves disrupting the tumor vasculature and inducing direct cytotoxicity to cancer cells, thereby offering a distinct therapeutic strategy for these challenging hematologic conditions.

• CA4P

  CA4P is an investigational drug for the treatment of advanced metastatic melanoma, focusing on the disruption of tumor blood supply. Through targeting the tumor vasculature, CA4P aims to starve tumor cells by cutting off their blood supply, a method known as vascular disrupting agent (VDA) therapy.

• Intranasal Drug and Delivery System for Apomorphine

  Developing an intranasal drug delivery system for apomorphine represents Oncotelic’s commitment to innovative therapies for neurological disorders. Aimed at treating Parkinson's Disease, erectile dysfunction, and female sexual dysfunction, this approach highlights the potential benefits of targeted drug delivery systems in improving patient outcomes and quality of life.

• Artemisinin

  A natural derivative from the Asian herb Artemisia Annua, Artemisinin embodies Oncotelic’s exploration into natural compounds for medical use. The company aims to leverage AI-based technologies to enhance the development and commercialization of Artemisinin-based products, demonstrating a novel pathway in drug discovery and development that combines traditional remedies with modern science.